Inflammation and the Incidence of Type 2 Diabetes

OBJECTIVE Many studies have documented associations between inflammation and type 2 diabetes incidence. We assessed potential variability in this association in the major U.S. racial/ethnic groups. RESEARCH DESIGN AND METHODS Incident type 2 diabetes was assessed among men and women aged 45–84 years without prior clinical cardiovascular disease or diabetes in the prospective Multi-Ethnic Study of Atherosclerosis. Interleukin (IL)-6, fibrinogen, and C-reactive protein (CRP) were measured at baseline (2000–2002); fasting glucose and diabetes medication use was assessed at baseline and three subsequent in-person exams through 2007. Type 2 diabetes was defined as use of diabetes drugs or glucose ≥126 mg/dl. Covariates included baseline demographics, clinic, smoking, alcohol, exercise, hypertension medication, systolic blood pressure, insulin resistance, and BMI. Cox proportional hazards regression was used to calculate hazard ratios (HRs) by quartiles of CRP, IL-6, and fibrinogen. RESULTS Among 5,571 participants (mean age 61.6 years, 53% female, 42.1% white, 11.5% Chinese, 25.7% black, and 20.7% Hispanic), 410 developed incident diabetes during a median follow-up time of 4.7 years (incidence 16.8 per 1,000 person-years). CRP, IL-6, and fibrinogen levels were associated with incident diabetes in the entire sample. After adjustment, the associations were attenuated; however, quartile 4 (versus quartile 1) of IL-6 (HR 1.5 [95% CI 1.1–2.2]) and CRP (1.7 [1.3–2.4]) remained associated with incident diabetes. In stratified analyses, similar associations were observed among white, black, and Hispanic participants. CONCLUSIONS Higher levels of inflammation predict short-term incidence of type 2 diabetes in a multiethnic American sample.

[1]  O. Franco,et al.  Associations of inflammatory factors with glycaemic status among middle‐aged and older Chinese people , 2009, Clinical endocrinology.

[2]  J. Manson,et al.  A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women , 2009, Diabetes Care.

[3]  T. Valle,et al.  Anti-inflammatory effect of lifestyle changes in the Finnish Diabetes Prevention Study , 2009, Diabetologia.

[4]  J. Manson,et al.  A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. , 2007, Archives of internal medicine.

[5]  Ralph B D'Agostino,et al.  Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. , 2007, Archives of internal medicine.

[6]  J. Leahy.  Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population: National Health and Nutrition Examination Survey 1999–2002 , 2007 .

[7]  A. Karter,et al.  Prediction of Type 2 Diabetes Mellitus With Alternative Definitions of the Metabolic Syndrome: The Insulin Resistance Atherosclerosis Study , 2005, Circulation.

[8]  T. Mandrup-Poulsen,et al.  Interleukin-6 and diabetes: the good, the bad, or the indifferent? , 2005, Diabetes.

[9]  L. Chambless,et al.  Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. , 2005, Diabetes.

[10]  M. Kubo,et al.  Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. , 2005, Diabetes care.

[11]  E. Yeh,et al.  Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. , 2005, Journal of the American College of Cardiology.

[12]  M. Rutter,et al.  C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study , 2004, Circulation.

[13]  Nader Rifai,et al.  Inflammatory markers and risk of developing type 2 diabetes in women. , 2004, Diabetes.

[14]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[15]  J. Newland.  Screening for high blood pressure: recommendations and rationale. , 2004, American family physician.

[16]  U. P. S. T. Force.  Screening for high blood pressure: recommendations and rationale. , 2003, American journal of preventive medicine.

[17]  T. Lam,et al.  C-reactive protein predicts the deterioration of glycemia in chinese subjects with impaired glucose tolerance. , 2003, Diabetes care.

[18]  T. Funahashi,et al.  Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. , 2003, Diabetes care.

[19]  Joachim Spranger,et al.  Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. , 2003, Diabetes.

[20]  C. Meisinger,et al.  C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. , 2003, Archives of internal medicine.

[21]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[22]  S. Haffner,et al.  Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.

[23]  L S Geiss,et al.  Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. , 2001, Diabetes care.

[24]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[25]  M. Cushman,et al.  Laboratory methods and quality assurance in the Cardiovascular Health Study. , 1995, Clinical chemistry.